Sionna Stock 144% This Year: Is the Biotech a Buy Now?
Sionna Therapeutics has surged 144% over the past year, drawing attention from growth-minded investors. This article ...
Identify the Dividend Aristocrats ETF with the lowest fees and understand how fee selection affects long-term performance.
27,609 articlesSionna Therapeutics has surged 144% over the past year, drawing attention from growth-minded investors. This article ...
Analysts see SpaceX, OpenAI, and Anthropic pursuing record mega-IPOs in 2026, potentially reshaping liquidity for ven...
Starbucks CEO Brian Niccol says the company drifted into factory-like operations. He outlines a reset designed to rec...
Progressive lawmakers unveiled a bill to halt new data centers for two years while federal safeguards for energy, lab...
Solana SOL faces a pivotal test as the $90 floor flips to a ceiling while trading volume wanes. Analysts warn that th...
AMD delivered a strong Q1 FY2026, prompting a broad uprising in analyst targets. Nine firms boosted price targets as ...
As 2026 unfolds, smart glasses are poised for a pivotal year, led by Meta and Google. Apple sits on the sidelines wit...
As markets wobble in 2026, suze orman’s sober advice guides grieving spouses to pause large financial actions for six...
The Clarity Act is moving toward markup with more than 100 amendments, spotlighting a fierce clash over stablecoin re...
California Governor Gavin Newsom unveils a $350 billion budget designed to erase deficits, broaden reserves, and prot...
A notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
Insider moves can signal confidence, but they aren’t a surebet. This guide shows you how to interpret a director purc...